摘要:
The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof: ##STR1## wherein Z, E, Q, T, U, V and L are as defined herein; processes for its preparation and its use in the treatment of conditions for which the administration of an agonist selective for the 5-HT.sub.1D.alpha. receptor subtype is indicated, such as migraine.
摘要:
Compounds of formula I: are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
摘要:
The present invention provides compounds of formula I: in which: one of X and Y is a nitrogen atom substituted by a group R6′ and the other is a carbon atom substituted by an isoxazole group substituted on its carbon atoms by groups R3 and R4;one of R6 and R6′ is hydrogen;either all of W1, W2, W3 and W4 are carbon or one of W1, W2, W3 and W4 is nitrogen and the rest are carbon;and R1 and R2 are, independently, a small group, heteroaromatic ring or a 4–7 membered cyclic amine ring; processes for making them; pharmaceutical composition containing them; their use in therapy, particularly for enhancing cognition in conditions such as Alzheimer's Disease; and methods of treatment using them.
摘要翻译:本发明提供式I化合物:其中:X和Y之一是被基团R 6'取代的氮原子,另一个是被其上取代的异恶唑基团取代的碳原子 通过R 3和R 4基团的碳原子; R 6和R 6之一是氢; W 1,W 2,W 3和W 4中的全部是碳或W SUP中的一个 W 1,W 2,W 3和W 4是氮,其余是碳; R 1和R 2独立地是小组杂芳族环或4-7元环胺环; 制作过程; 含有它们的药物组合物; 它们在治疗中的用途,特别是用于增强诸如阿尔茨海默氏病等疾病的认知; 和使用它们的治疗方法。
摘要:
A substituted triazolopyridazine derivative, its use in cognition enhancement therapy, compositions containing it and processes for its manufacture.
摘要:
Compounds of formula I: are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
摘要:
Compounds of formula I: are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
摘要:
A class of substituted imidazolo[5,1-a]phthalazine derivatives as ligands for GABAA receptors of formula I which are partial or full inverse agonists of an α5 receptor subunit while being relatively free of activity at α1 and/or α2 and/or α3 receptor subunit binding sites are described herein; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of proconvulsant activity.
摘要翻译:一类取代的咪唑并[5,1-a]酞嗪衍生物作为式I的GABA A A受体的配体,其是α5受体亚基的部分或完全反向激动剂,而在α1相对没有活性 和/或α2和/或α3受体亚单位结合位点; 因此,它们作为增强认知但减少或消除促凝血活性的药物是有益的。
摘要:
The present invention relates to compounds of the formula (I): ##STR1## wherein Ar.sup.1 represents optionally substituted phenyl; Ar.sup.2 represents aryl; benzhydryl; or benzyl; wherein each aryl and heteroaryl and each phenyl moiety of benzyl and benzhydryl may be substituted; R.sup.1 represents H or a group of the formula Z-R.sup.2 ; R.sup.2 represents H, CO.sub.2 R.sup.7, CONR.sup.7 R.sup.8, NR.sup.7 R.sup.8, NR.sup.7 COR.sup.9, NR.sup.7 SO.sub.2 R.sup.8, trifluoromethyl, heteroaryl or --O-heteroaryl, each of which heteroaryl groups are as previously defined and may be optionally substituted, or R.sup.2 represents a group selected from phenyl, piperazinyl, piperidinyl, spiro-fused piperidinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl, each of which may be substituted; R.sup.3, R.sup.4, R.sup.5 and R.sup.6 each independently represent H or C.sub.1-4 alkyl; R.sup.7 and R.sup.8 each independently represent H, C.sub.1-6 alkyl, trifluoromethyl, phenyl or benzyl; Q represents O or S; X represents a group selected from --CR.sup.3 R.sup.4 CR.sup.5 R.sup.6 -, --CR.sup.3 .dbd.CR.sup.4 --, --C(OH)R.sup.3 CR.sup.4 R.sup.5 -, --CR.sup.3 R.sup.4 C(OH)R.sup.5 -, --C(O)CR.sup.3 R.sup.4 - and --CR.sup.3 R.sup.4 C(O)--; Y represents a C.sub.1-4 alkylene chain; and Z represents a straight or branched C.sub.1-6 alkylene or C.sub.3-6 alkenylene chain with the proviso that the alkenylene double bond does not terminate at a carbon atom attached to a nitrogen atom; and pharmaceutically acceptable salts thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, emesis and postherpetic neuralgia.
摘要翻译:本发明涉及式(I)的化合物:其中Ar 1表示任选取代的苯基; Ar2表示芳基; 二苯甲基 或苄基; 其中苄基和二苯甲基的每个芳基和杂芳基和每个苯基部分可以被取代; R1表示H或式Z-R2的基团; R 2表示H,CO 2 R 7,CONR 7 R 8,NR 7 R 8,NR 7 COR 9,NR 7 SO 2 R 8,三氟甲基,杂芳基或-O-杂芳基,其各自的杂芳基如前所定义,并且可以是任选取代的,或者R 2表示选自苯基,哌嗪基, ,螺 - 稠的哌啶基,四氢喹啉基或四氢异喹啉基,其各自可以被取代; R3,R4,R5和R6各自独立地表示H或C1-4烷基; R 7和R 8各自独立地表示H,C 1-6烷基,三氟甲基,苯基或苄基; Q表示O或S; X表示选自-CR 3 R 4 CR 5 R 6 - , - CR 3 = CR 4 - , - C(OH)R 3 CR 4 R 5 - , - CR 3 R 4 C(OH)R 5 - , - C(O)CR 3 R 4 - 和-CR 3 R 4 C(O) - 的基团。 Y表示C1-4亚烷基链; 并且Z表示直链或支链C 1-6亚烷基或C 3-6亚烯基链,条件是亚烯基双键不在与氮原子连接的碳原子上终止; 及其药学上可接受的盐。 该化合物特别用于治疗或预防疼痛,炎症,呕吐和带状疱疹后神经痛。
摘要:
The present invention relates to compounds of formula I: in which R1 is a linear group or a five membered heterocycle optionally fused to a phenyl ring, R2 is a 5-membered heterocycle, R3 is chosen from a range of substituents, m is 0–3 and n is 0 or 1; the compounds are generally inverse agonists at GABA-A receptors containing the alpha 5 subunit and so are useful in methods of enhancing cognition in subjects with diminished cognition in diseases such as Alzheimer's Disease.
摘要翻译:本发明涉及式I化合物:其中R 1是线性基团或任选地与苯环稠合的五元杂环,R 2是5- R 3选自一系列取代基,m为0-3,n为0或1; 该化合物通常是含有α5亚基的GABA-A受体的反向激动剂,因此可用于增强患有阿尔茨海默病等疾病认知减退的受试者的认知的方法。